ID
9921
Description
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel(TM)) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Keywords
Versions (5)
- 3/4/15 3/4/15 -
- 3/9/15 3/9/15 -
- 4/23/15 4/23/15 -
- 12/9/15 12/9/15 -
- 2/11/16 2/11/16 -
Uploaded on
March 4, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Concomitant Medication AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)
Concomitant Medication AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)
Description
Signature
Description
Date
Data type
date
Alias
- UMLS CUI-1
- C2346576 (Investigator Signature)
- UMLS CUI-2
- C0011008 (Date in time)
- SNOMED
- 410671006
Description
Name and Signature of Investigator
Data type
text
Alias
- UMLS CUI-1
- C0027365 (Name)
- SNOMED
- 703503000
- LOINC
- LP72974-6
- UMLS CUI-2
- C1519316 (Signature)
- LOINC
- LP248948-4
- UMLS CUI-3
- C0031831 (Physicians)
- SNOMED
- 158965000
- LOINC
- LA18968-0
Similar models
Concomitant Medication AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)
C0282291 (UMLS CUI-2)
C0802004 (UMLS CUI-2)
C0806020 (UMLS CUI-2)
C0011008 (UMLS CUI-2)
C1519316 (UMLS CUI-2)
C0031831 (UMLS CUI-3)
No comments